Xtra-Gold Resources Corp. (XTG) Lifts Kibi Indicated Gold Resource to 1.40Moz

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity after regulatory approval and NHI listing. This is the first approved therapy in Japan for this condition, marking the company's geographic expansion of setmelanotide. Investors will watch for uptake metrics and revenue contributions in future quarters.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.

Space Norway has chosen Ciena (NYSE: CIEN) to upgrade its Svalbard subsea cable systems and deploy new technology on the Arctic Way system, set to launch in 2028. The project aims to extend the operational life of existing infrastructure and enhance connectivity in the Arctic. Ciena will provide design, deployment, and optical technology, including the Ciena 6500 Optical Platform and Navigator Network Control Suite, to improve network resilience and capacity.

BioNTech (BNTX) shares dropped 7% after its mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival benefit in a late-stage trial. Analysts noted broader challenges for mRNA cancer vaccines, while the company continues to assess overall survival data. Analysts' price targets range from $105 to $130.

Leidos (LDOS) won a $318M contract from the Defense Health Agency for MHS GENESIS support. LDOS trades at $119.70, 30.7% below its GF Value™ of $172.78, with a GF Score™ of 85/100. Insiders sold $3.2M in shares over 12 months. The company serves government clients, with revenue from long-term contracts.

Lockheed Martin (LMT) won an $117.1M U.S. Army contract for Apache helicopter radar support, extending through 2031. The company offers a 2.69% dividend yield, a 50% payout ratio, and a 5.4% 3-year dividend growth rate. LMT's GF Score is 86/100, with strong profitability and valuation metrics. The stock is trading at a discount to its GF Value of $567.85. Institutional interest is mixed, with some gurus adding positions and insiders selling shares.